ITGB1P1: A Drug Target / Disease Biomarker (G100422691)

Target Name: ITGB1P1

NCBI ID: G100422691

ITGB1P1

Other Name(s): Integrin subunit beta 1 pseudogene 1 | integrin subunit beta 1 pseudogene 1 | ITGB1L | FNRBL

ITGB1P1: A Drug Target / Disease Biomarker

ITGB1P1, also known as CD73, is a protein that is expressed in the endothelial cells of the body. It is a member of the Integrin alpha-2 (ITGA) family, which is known for its role in cell-cell and cell-extracellular matrix adhesion. ITGB1P1 has been shown to be involved in several physiological processes in the body, including blood vessel formation, angiogenesis, and tissue repair.

One of the most promising aspects of ITGB1P1 is its potential as a drug target. ITGB1P1 has been shown to be involved in several diseases and conditions, including cancer, cardiovascular disease, and neurodegenerative diseases. Its role in these conditions makes it an attractive target for drug development.

One of the ways that ITGB1P1 is being targeted as a drug is through its role in cancer. ITGB1P1 has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer. Studies have shown that inhibiting ITGB1P1 can lead to a reduction in the growth and spread of these cancers. This is because ITGB1P1 plays a role in the formation of blood vessels, which provide a source of oxygen and nutrients for cancer cells.

Another potential mechanism by which ITGB1P1 may be used as a drug is its role in cardiovascular disease. ITGB1P1 has been shown to be involved in the regulation of blood vessel diameter and blood pressure, which are important factors in the development of cardiovascular disease. Studies have shown that inhibiting ITGB1P1 can lead to a reduction in the risk of cardiovascular disease in individuals with certain genetic predispositions.

ITGB1P1 has also been shown to be involved in neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. ITGB1P1 has been shown to be involved in the development and progression of these conditions, and may be a potential target for new treatments.

In addition to its potential as a drug target, ITGB1P1 has also been shown to have several potential therapeutic applications in other areas. For example, ITGB1P1 has been shown to be involved in the regulation of inflammation, which is important for the development of many diseases. Studies have shown that inhibiting ITGB1P1 can reduce the production of pro-inflammatory molecules and improve the response of the immune system to infection.

ITGB1P1 has also been shown to be involved in the regulation of stem cell proliferation and differentiation. These processes are important for the development and maintenance of tissues and organs, and are critical for the growth and development of many diseases. Studies have shown that inhibiting ITGB1P1 can lead to a reduction in the production of stem cells and their differentiation into functional tissues.

In conclusion, ITGB1P1 is a protein that has been shown to be involved in several physiological processes in the body. Its potential as a drug target makes it an attractive target for the development of new treatments for a wide range of conditions. While further research is needed to fully understand the role of ITGB1P1 in the body and its potential as a drug, its potential as a therapeutic target is already a promising area of research.

Protein Name: Integrin Subunit Beta 1 Pseudogene 1

The "ITGB1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGB1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets